[ad_1]
THURSDAY, Jan. 21, 2021 (HealthDay News) – Serotonin-norepinephrine reuptake inhibitors (SNRIs) have a minor and not clinically important effect on back pain, but may have a clinically important effect on osteoarthritis, according to one journal published online in January. 20 in BMJ.
Giovanni E. Ferreira, University of Sydney, and colleagues conducted a systematic review and meta-analysis of randomized controlled trials of any antidepressant drug in patients with lower back or neck pain, sciatica or osteoarthritis. hip or knee. Data were included for 33 trials with 5,318 participants.
Researchers found that, based on moderate and low-certainty evidence, SNRIs reduced back pain (mean difference, -5.30) and osteoarthritis pain (-9.72), respectively, between three and 13 weeks . Based on very low-certainty evidence, SNRIs reduced sciatica to two weeks or less (-18.60), but not three to 13 weeks. Tricyclic antidepressants did not reduce sciatica at two weeks or less, but did reduce sciatica at three to 13 weeks and three to 12 months (-15.95 and -27.0, respectively) based on the evidence low to very low certainty. Based on moderate certainty evidence, SNRIs reduced disability from back pain after three to 13 weeks (-3.55); disability due to osteoarthritis was reduced to two weeks or less and three to 13 weeks (-5.10 and -6.07, respectively) based on moderate and low-certainty evidence, respectively.
“Large definitive randomized trials, free of any industrial link, are urgently needed to resolve the uncertainties about the efficacy of antidepressants for sciatica and osteoarthritis highlighted by this review,” write the authors.
GlaxoSmithKline, Pfizer and Flexeze provided support for the study.
Summary / Full text
Editorial
Source link
